CEL-SCI (CEL-SCI) YoY EBITDA Growth : 26.45% (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. CEL-SCI's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 26.45%.

CEL-SCI's EBITDA per Share for the three months ended in Dec. 2023 was $-0.11.

CEL-SCI YoY EBITDA Growth Historical Data

The historical data trend for CEL-SCI's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI YoY EBITDA Growth Chart

CEL-SCI Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

YoY EBITDA Growth

Get a 7-Day Free Trial

33.33

-16.46

-10.05

9.01

15.88

CEL-SCI Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															12.43	17.09	8.94	24.18	26.45

CEL-SCI YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

CEL-SCI's YoY EBITDA Growth for the fiscal year that ended in Sep. 2023 is calculated as:

	YoY EBITDA Growth (A: Sep. 2023 )
=	(EBITDA per Share (A: Sep. 2023 )	-	EBITDA per Share (A: Sep. 2022 ))	/	\| EBITDA per Share (A: Sep. 2022 ) \|
=	(-0.62	-	-0.737)	/	\| -0.737 \|
=	15.88 %

CEL-SCI's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.114	-	-0.155)	/	\| -0.155 \|
=	26.45 %

CEL-SCI YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of CEL-SCI's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI (CEL-SCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

LSRM:Germany LSRM:Germany

Address

8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182

Website

https://www.cel-sci.com

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Executives

Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano	officer: Senior Vice President	8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson	director	245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine	director	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor	officer: Chief Scientific Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten	director, officer: Chief Executive Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman	officer: Sr. Vice President, Research	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep	officer: Sr. Vice President, Operations	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De	director, officer: President
C Richard Kinsolving	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182